logo
Gynaecological cancer survivors help educate Australia's future doctors and nurses

Gynaecological cancer survivors help educate Australia's future doctors and nurses

When Kristin Young was diagnosed with stage 3 ovarian cancer in 2009, it had taken her doctors some time to figure out what was wrong.
"Ovarian cancer is difficult to pick up and often thought to be other things," she said.
"The most common symptoms — bloating, feeling full [quickly] and the need to urinate more often … they present like other common conditions."
In Kristin's case, it was a much rarer symptom — swollen lymph nodes in her groin — that prompted concern.
"The really tricky thing about ovarian cancer is it manifests in many different ways … and spreads quite widely before it ever gets big enough to give you a symptom," she said.
"Many women have hoped that the medical system would do better to pick it up early, but the system is up against the perplexing biology of ovarian cancer, which is worsened by its rarity."
Kristin underwent treatment, which was successful, but 4.5 years later, the cancer returned.
The now-retired psychologist said one of the biggest challenges of dealing with a cancer diagnosis was navigating the health system and "getting the right communication" with her medical team.
When an opportunity came up to work with trainee health professionals to improve their understanding of gynaecological patients' lived experiences, Kristin knew she wanted to be involved.
"One of the really important things … is to share that message that [ovarian cancer] is difficult to diagnose, and how important it is to listen to the stories that women bring to the doctor," she said.
"If, through education and awareness, we can help a small number of people be diagnosed even a bit earlier, it's better than things staying the way they are."
The volunteer-led program, Survivors Teaching Students, is a national initiative that brings ovarian and other gynaecological cancer survivors and caregivers into the classrooms of medical, nursing and other health professional students across the country.
Alison Evans, CEO of the Australian and New Zealand Gynaecological Oncology Group (ANZGOG), said the program was developed by the Ovarian Cancer Research Alliance in the US and brought to Australia by ANZGOG in 2017.
"It's vital because it's really giving voice to what symptoms are, what diagnosis looks like, and what treatment looks like from a patient's perspective," Ms Evans told the Health Report.
In Australia, 19 women are diagnosed and six women die from gynaecological cancer every day.
Despite this, Ms Evans said gynaecological cancers — which include uterine, endometrial, ovarian, vulval, vaginal and cervical — were poorly understood in the community.
"There's a stigma around these cancers because they are part of the reproductive system, and therefore they're hidden and they're very personal," she said.
With the exception of cervical screening, there are no early detection tests available, and as a result, gynaecological cancers often grow silently during the curable stage.
Adding to the challenge is the fact women may have symptoms overlooked or minimised by health professionals, which Ms Evans hopes the program will help to change.
Since 2017, Survivors Teaching Students volunteers have delivered in-person and online programs to more than 20,000 students across 22 universities in Australia and New Zealand.
During a typical session, students hear from three volunteers — including patients, carers and family members — about their personal experience with gynaecological cancer, including the physical, mental and emotional toll it takes.
"Patients are real people with lives and families, and we want the doctors and nurses of the future to see that," Kristin said.
One of the key goals, she said, is to emphasise the importance of good health communication and compassionate care.
"Patients remember what doctors and nurses say, and that sometimes can be engraved in your mind forever."
But the most important part, according to Kristin, is answering the questions from students.
"Many students are really touched at an emotional level … and perhaps start to think they would consider a career in oncology or oncology-based research."
Further research was critical for early detection and treatment options to be improved, Ms Evans said, particularly for the 55 per cent of gynaecological cancers considered rare or less common, which often had limited treatment options.
"We want doctors to be curious about these diseases for the rest of their career," she said.
"The most important thing is that GPs and nurses … have a voice in their head that is the woman's voice or the carer's voice that they take with them."
Kristin said her own experience with ovarian cancer was proof that oncology research was having an impact.
"I'm a 'super responder' on one of these new molecular-based treatments … so the prognosis that I had, which was very poor, I have now outlived this, and I know that that represents hope," she said.
"Research is prolonging lives in some people and with more research it will prolong more lives."
In addition to inspiring and educating the next generation of health professionals, she said the Survivors Teaching Students program had strengthened the community of people living with gynaecological cancer.
"At the very personal level, I have made good friends, what I feel are lifelong friends.
"The term lifelong is ironic in ovarian cancer because many of the women I have met … unfortunately have not had long lives. I have my contacts list and my phone is full of people who have passed away, but I never delete them."
The program helped people affected by gynaecological cancer leave a "lasting legacy", Ms Evans added.
"Many women and their families at the end of treatment are looking for a way to make a difference.
Listen to the full story and subscribe to the Health Report podcast for more.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ultrahuman Ring Air Review: Lightweight & Innovative Smart Ring
Ultrahuman Ring Air Review: Lightweight & Innovative Smart Ring

News.com.au

time2 hours ago

  • News.com.au

Ultrahuman Ring Air Review: Lightweight & Innovative Smart Ring

These products are hand-picked by our team to help make shopping easier. We may receive payments from third parties for sharing this content and when you purchase through links in this article. Product prices and offer details are not assured, and should be confirmed independently with the retailer. Learn more As I barrel through my 30s at an alarming rate, I've realised something that feels very adult to admit: your health and wellbeing actually matter (shocking, I know). I've never been into fitness trackers – I've so far resisted the Apple Watch – but this year I kept hearing whispers about smart rings. Suddenly, they were everywhere and I found myself … ring-curious. A smart ring appealed to me instantly. Instead of a chunky, ugly watch screaming “fitness trackerâ€� to the world, a ring felt understated, sleek and actually wearable 24/7 (I refuse to wear a watch to sleep). More importantly, the focus wasn’t just on fitness metrics but on overall wellbeing: sleep, stress, recovery, temperature, even cycle tracking. That’s the stuff I actually cared about. So, I took the plunge and got myself an Ultrahuman Ring AIR. Unlike the popular Oura Ring, it’s a one-time purchase â€' no subscription fees â€' and promises all the same insights (plus a few extra). Three months later, I can honestly say it’s life-changing. My sleep has improved dramatically and I feel more in tune with my body day to day. To see if it could do the same for others, I roped in lifestyle reporter Eleanor Wicklund to test it out too. THE RUNDOWN Ultrahuman Ring Air $599 at Amazon Other ways to buy: For anyone serious about sleep and overall wellbeing over fitness metrics Tried and Tested by Melody Teh, checkout Deputy Editor I am, in a word, obsessed. These days, the first thing I check in the morning isn’t social media but my Ultrahuman app to see my sleep score. Hooked? Definitely. But also, incredibly helpful. Being able to see exactly how I slept â€' my sleep cycles, how quickly I drifted off, when my heart rate dropped, how often I tossed and turned â€' has made me far more conscious of my sleep and how to improve it. Like most wearables, the Ultrahuman Ring AIR gives you all the health insights you want: heart rate, body temperature, stress, sleep, recovery scores and so on. But what sets it apart is how it interprets your data. Instead of throwing generic tips at you, it makes personalised suggestions. If you’ve built up sleep debt, it’ll nudge you towards an earlier bedtime. Rested and recovered? Your “caffeine windowâ€� extends. It sends weekly reports with practical ways to tweak your routine. Honestly, the caffeine guidance alone has been a game-changer for my energy levels. That’s not to say it’s perfect. Step tracking is the weakest point. I often find it wildly overcounts compared with my iPhone, which makes me less inclined to trust it. And, like any ring, it’s not ideal for weightlifting. I prefer to take it off so it doesn’t get scratched or dig into my fingers. On runs though, it’s excellent: heart rate zones, average pace, routes â€' all tracked accurately. I particularly love the cycle tracking. It uses biomarkers like temperature and HRV to suggest when to rest or push harder. It even picked up when I was coming down with something based on a temperature shift. When you add in circadian rhythm insights, sun exposure tracking (I was shocked by how little winter light I was getting), and stress monitoring, this ring lets you see the full picture on your health and wellbeing. After three months of wearing it every single day, I’m 100 per cent convinced this smart ring is absolutely worth it. It doesn’t broadcast “fitness tracker,â€� it’s comfortable to wear 24/7 and it genuinely helps me improve my health with minimal effort. For anyone who wants data-driven health insights without looking like a tech gadget Tried and Tested by Eleanor Wicklund, Lifestyle Reporter I’ve never been into wearables. Smartwatches look like you’re in Spy Kids, and fitness bands remind me of the 10,000-step craze, and the whole thing feels … a bit Silicon Valley tech bro. But the Ultrahuman Ring AIR feels different. It’s gold (to match my jewellery), ultralight, and subtle enough that it mostly passes as a chic accessory. Until someone asks what it is â€' at which point, I get to smugly explain it’s an Ultrahuman ring, which sounds badass. Unlike most trackers obsessed with steps and calories, the Ultrahuman Ring Air focuses on the often overlooked metrics that actually impact how you feel day-to-day. Sleep quality, stress rhythm, heart rate variability, recovery … the less sexy stuff, but the insights that will actually explain why you’re either thriving or crashing. The sleep insights are my favourite. It doesn’t just give me a quantifiable score, which I can use to compete, I mean compare with my husband’s, but it actually breaks down my REM, deep sleep and restlessness. It even counts my sleep cycles â€' which is so helpful in working out why I might feel groggy on some mornings, despite getting my eight hours. It’s also strangely motivating â€' like something I want to secretly impress. Seeing my caffeine window closing makes me want to make a Sensible Decision and turn down that 3pm matcha like a responsible adult. Every time I do, I feel like I get a metaphorical gold star from my little ring, and it’s an incentive to keep behaving. Same for my workouts. Whether I’m doing rhythm riding or weights, I can see how hard I’ve pushed and how well I’m recovering, based on different things like sleep or going to the sauna. On long office days, it reminds me to get up and actually see the outside world. It’s a polite nudge, but one I’ve actually started listening to. I will say, when I first looked at the app’s interface, it was a tad overwhelming. There’s A LOT this ring can track. But my advice is to focus on the things you actually care about, and don’t get bogged down in the stuff you don’t. Overall, I’d definitely recommend this ring if you’re after an accessible biohacking device that not only looks good but also tracks accurately and provides valuable insights to help optimise your life. How easy is it to set up? Melody: Before you commit, I’d recommend getting the $10 sizing kit. It comes with ten sample rings to test over a couple of days (definitely sleep in them to see how they feel as that’s when I noticed comfort most). You also get colour samples to help you choose. Once I’d picked my size, the ring came quickly and setup was a breeze: charge the ring, download the app, pair, and wear. Lots of data like sleep, heart rate and stress show up straight away but it takes a couple of weeks to build a really accurate picture of your health. Eleanor: Surprisingly yes. The sizing kit arrives first, so you’re not left guessing which ring size you are, or awkwardly measuring your finger with a piece of string. Once it arrives, charging it and pairing it with the app takes maybe five minutes, and you’re basically off. When it’s charged, you literally just pop on the ring and it’s good to go. What does it look and feel like? Melody: The ring is made from titanium and weighs between 2.4-3.6 grams â€' it’s seriously lightweight. It comes in six colours: Air Gold, Rose Gold, Air Silver, Raw Titanium, Aster Black, and Matte Grey. It’s sleek, subtle and also waterproof so you can wash your hands, shower and swim without taking it off. Eleanor: It’s discreet enough that it could just look like any other gold ring, but unique enough that those in the know will instantly recognise it as a smart ring. You see, it doesn’t look particularly techy, unless you look on the inside of it, so you can get away with wearing it with more dressy outfits and it blends in seamlessly with your other accessories. How's the battery life? Melody: Ultrahuman claims the battery lasts four to six days, but in reality I found it got closer to three on full mode. Switching to “Chill Modeâ€� (which scales back certain features) stretched it much further but I preferred the extra insights from full mode. Be aware that workout mode drains it quicker. Charging is easy â€' simply pop it on the included dock and it’s full in about three hours. The app also gives you a low battery notification at 30 per cent. Eleanor: One thing I like about this ring (as opposed to a fitness watch I’ve owned in the past) is just how long the battery life lasts. It sees me through easily from Monday through Friday, meaning I charge it on the weekend and am ready to go for the next week. I also liked that you could choose battery usage modes, depending on how you use your ring the most, to stretch the battery life even further. Do you need the app? Yes, the Ultrahuman app is where all your data lives. This is where you’ll see all your metrics in one easy-to-digest feed. If you want more detail, you can tap on any card to dive deeper. At the top of the app, there’s a calendar view so you can compare your stats week by week, and the profile tab gives you full weekly reports. The app also comes with bonus “plug-inâ€� tools like caffeine tracking, plus free workout content including HIIT, pilates, yoga, meditation, and breathwork. How does it compare to the Oura Ring? I haven’t personally worn an Oura but on paper the Ultrahuman has many of the same health and wellness features. The biggest win? No subscription fees. Oura requires a monthly membership to access your data while Ultrahuman Air Ring is a one-time purchase. Once you factor in ongoing costs, Ultrahuman actually works out cheaper. Is is worth it? Melody: For me, yes. The Ultrahuman AIR Ring has made me sleep better, feel better, and actually understand my body. I love that it focuses on overall wellbeing and it’s genuinely been useful in helping me reduce stress, lower my heart rate and get better sleep. It’s sleek, comfortable, and doesn’t scream “fitness trackerâ€� so I’ve happily worn in 24/7 for the last three months and will continue to do so. There’s no denying it’s expensive piece of tech, but for anyone curious about smart rings, this ring is a game-changer and one of the smartest health investments you can make. Eleanor: If you want something that just counts steps, this isn’t it. But if you want to get into the nitty gritty of your health, then this is for you. It’s perfect for data-curious types, people flirting with biohacking and anyone who has found themselves saying more often than not, “I should really stop doomscrolling and get more sleepâ€�.

Health Check: ‘Historical milestone' as FDA approves second Artrya heart device
Health Check: ‘Historical milestone' as FDA approves second Artrya heart device

News.com.au

time2 hours ago

  • News.com.au

Health Check: ‘Historical milestone' as FDA approves second Artrya heart device

Artrya shares surge up to 42% on FDA clearance of the company's Salix Coronary Plaque device Sonic Healthcare joins CSL in the healthcare sin bin Universal Biosensors calls in the corporate undertakers Artrya (ASX:AYA) has won US Food and Drug Administration (FDA) approval for a second heart disease detection device, thus paving the way for attractive per-scan fees. The agency has given the nod to the company's AI-powered Salix Coronary Plaque (SCP) module, for the 'near real time, point of care assessment and management of coronary artery disease'. Artrya lodged the application under the 510(k) predicate device route only on June 16, so it was a quick turnaround from the stretched FDA. High-risk plaque is a key indicator of heart disease, yet it's often missed by current surveillance means. Put bluntly, for half of these patients the initial symptom is death. SCP will provide clinicians with a highly detailed assessment of coronary artery plaque in under ten minutes. The device will integrate with FDA-cleared Salix Coronary Anatomy (SCA) platform, which has been sold in the US since July. SCA analyses data from computed tomography (CT) scans, so is not so real time-ish. Expanding revenue Artrya says the latest approval will 'greatly expand the revenue opportunity with current and future customers'. Getting to the pointy end of things, SCP is eligible for category one reimbursement of US$950 per assessment (for Artrya's customers). 'We are thrilled to have received clearance … which opens up a much greater revenue opportunity for us in the US, our largest market,' trills Artrya co-founder and CEO John Konstantopoulos. Artrya is tackling the US market via partnerships with mid-sized hospital groups. The first of these, Tanner Health, signed a deal to use SCA in July. Northeast Georgia Health and Cone Health followed suit. Petra Capital analyst Tanu Jain dubs the SCP approval as 'another historic milestone' for Artrya that 'material changes' the company's prospects. SCP accounts for more than 70% of the firm's forecast US revenues for Artrya: $100 million by June 2029. And there's more: the company expects the FDA to approve a third device – Salix Coronary Flow – early next year. Sonic shares don't boom Sonic Healthcare (ASX:SHL) has become the second healthcare giant to disappoint this week, following CSL's (ASX:CSL) damp squib on Tuesday. The company's shares tumbled around 10% this morning after the pathology (and radiology) services giant reported a 7% boost in full-year earnings to $514 million. Revenue gained 8% to $9.64 million. Surely punters would be happy with a single digit increment in these challenged times? But it was the usual story of the profit falling short of consensus expectations, of around $530 million. RBC Capital Markets says the result was 'disappointing'. But to be fair, the market expectations were above what management itself was guiding. Sonic now has guided to underlying earnings (EBITDA) of $1.87-1.95 billion for the current year, compared with $1.725 billion in 2024-25. That's an 11% improvement at the midpoint, but once gain investors had chalked in a bit more. Last month Sonic completed the purchase of LADR, one of Germany's top five lab groups, for around €423 million ($760million) in a cash and scrip deal. Given LADR turned dover €370 million last and generated €50 million, the acquisition should add some Panzer grunt to current year performance. No pain, some gain at Medical Developments Purveyor of the well-established Penthrox front-line pain relief device, Medical Developments International (ASX:MVP) has managed a $100,000 full-year profit. While that seems modest, it's a welcome turnaround on the previous $41 million loss. The previous underlying loss (EBIT) improved to a $48,000 deficit after the previous $11.6 million shortfall. A.k.a 'the Green Whistle', the Penthrox analgesic dispensers are a common sigh on sporting sidelines, when stricken players hobble off sucking the devices. The company's overall revenue gained 18% to $39.1 million, with pain management (Penthrox) turnover surging 23% to $26.2 million. (The company also glean handy revenue from selling respiratory devices such as asthma spacers.) Management reports 'pleasing growth' in Europe and the UK. Locally, Penthrox revenue gained 26% to $15.4 million and the devices now account for 43% of the hospital segment. There's a big missing piece to the company's global jigsaw. Despite the ubiquitousness of Penthrox, US authorities refuse to approve it for historical reasons. Another one hits the rough Universal Biosensors (ASX:UBI) has called in KPMG's kindly voluntary administrators after failing to execute an urgent funding deal with an entity related to a director, Craig Coleman. The company had reported first-half revenue of $2.76 million, down 11% and a $10.48 million loss. The June 30 cash balance stood at less than $2.2 million. In the words of David Copperfield's Mr Micawber – a business consultant ahead of his time - 'annual income twenty pounds, annual expenditure twenty pounds nought and six, result misery'. The company said the administrators' current intention was 'to continue to trade UBS whilst an urgent assessment of trading is undertaken and options for its sale and, or recapitalisation are explored'. For the time being, the administration pertains to the local arm of the US-incorporated entity. Universal shares closed on Tuesday at 1.4c, ascribing a $5.4 million market cap. Over a convoluted 20-year listed history, Universal commercialised bio-chemical sensor technology for applications including blood coagulation, wine testing, water impurities and canine glucose levels. Sadly, the sector's casualty wards are filling. Last December Genetic Technologies entered voluntary administration. In December the company sold its key asset – its Genetype business – to Rhythm Biosciences (ASX:RHY) for $625,000. In May this year, medical cannabis play Ecofibre gave up the struggle and called in administrators. As did Cryogenic sample labelling play, Bluechiip. A slew of other biotech microcaps faces a similar fate if they don't raise funds pronto. But your columnist is too much of a gentleman to name them. Kiwi snore buster guides to 'very strong' conditions Ahead of its AGM later today, Kiwi based ResMed (ASX:RMD) rival Fisher & Paykel Healthcare (ASX:FPH) has guided to 31% profit surge in the current (September) half, with revenue up 13%. This equates to earnings of around NZ$200 million and turnover of $1.075 billion. CEO Lewis Gradon points to 'very strong' conditions across the homecare and hospital products group. The former includes continuous positive airway pressure pumps and masks for sleep apnoea; hence the rivalry with Resmed. Earlier this month, Resmed disclosed June (fourth) quarter revenue of US$1.3 billion, up 10% and a US$380 million net profit, up 30%. CEO Mick Farrell reported 'robust global demand for our market-leading sleep and breathing health devices, as well as our expanding digital health ecosystem.' The hospital group sells devices such as humidifies and masks. Gradon refers to an 'ongoing critical change' to hospital therapies which has provided a tailwind. RFK 'rhetoric' linked with Atlanta shooting In the latest missive from our overworked Washington desk, hundreds of health workers are imploring health secretary Robert F Kennedy Junior to tone down his rhetoric on vaccines after a fatal shooting. Earlier this month, a gunman opened fire at the Centers for Diseases Control and Prevention's Atlanta HQ, killing one policeman. The assailant, who then shot himself, reportedly believed the Covid-19 jab had made him sick. In a letter, more than 750 current and former federal health workers described JFK Jr as 'complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information.' The uber department, Human Health Services said the protests were an attempt to politicise a tragedy by conflating 'widely supported public health reforms with the violence of a suicidal mass shooter'.

Gynaecological cancer survivors help educate Australia's future doctors and nurses
Gynaecological cancer survivors help educate Australia's future doctors and nurses

ABC News

time8 hours ago

  • ABC News

Gynaecological cancer survivors help educate Australia's future doctors and nurses

When Kristin Young was diagnosed with stage 3 ovarian cancer in 2009, it had taken her doctors some time to figure out what was wrong. "Ovarian cancer is difficult to pick up and often thought to be other things," she said. "The most common symptoms — bloating, feeling full [quickly] and the need to urinate more often … they present like other common conditions." In Kristin's case, it was a much rarer symptom — swollen lymph nodes in her groin — that prompted concern. "The really tricky thing about ovarian cancer is it manifests in many different ways … and spreads quite widely before it ever gets big enough to give you a symptom," she said. "Many women have hoped that the medical system would do better to pick it up early, but the system is up against the perplexing biology of ovarian cancer, which is worsened by its rarity." Kristin underwent treatment, which was successful, but 4.5 years later, the cancer returned. The now-retired psychologist said one of the biggest challenges of dealing with a cancer diagnosis was navigating the health system and "getting the right communication" with her medical team. When an opportunity came up to work with trainee health professionals to improve their understanding of gynaecological patients' lived experiences, Kristin knew she wanted to be involved. "One of the really important things … is to share that message that [ovarian cancer] is difficult to diagnose, and how important it is to listen to the stories that women bring to the doctor," she said. "If, through education and awareness, we can help a small number of people be diagnosed even a bit earlier, it's better than things staying the way they are." The volunteer-led program, Survivors Teaching Students, is a national initiative that brings ovarian and other gynaecological cancer survivors and caregivers into the classrooms of medical, nursing and other health professional students across the country. Alison Evans, CEO of the Australian and New Zealand Gynaecological Oncology Group (ANZGOG), said the program was developed by the Ovarian Cancer Research Alliance in the US and brought to Australia by ANZGOG in 2017. "It's vital because it's really giving voice to what symptoms are, what diagnosis looks like, and what treatment looks like from a patient's perspective," Ms Evans told the Health Report. In Australia, 19 women are diagnosed and six women die from gynaecological cancer every day. Despite this, Ms Evans said gynaecological cancers — which include uterine, endometrial, ovarian, vulval, vaginal and cervical — were poorly understood in the community. "There's a stigma around these cancers because they are part of the reproductive system, and therefore they're hidden and they're very personal," she said. With the exception of cervical screening, there are no early detection tests available, and as a result, gynaecological cancers often grow silently during the curable stage. Adding to the challenge is the fact women may have symptoms overlooked or minimised by health professionals, which Ms Evans hopes the program will help to change. Since 2017, Survivors Teaching Students volunteers have delivered in-person and online programs to more than 20,000 students across 22 universities in Australia and New Zealand. During a typical session, students hear from three volunteers — including patients, carers and family members — about their personal experience with gynaecological cancer, including the physical, mental and emotional toll it takes. "Patients are real people with lives and families, and we want the doctors and nurses of the future to see that," Kristin said. One of the key goals, she said, is to emphasise the importance of good health communication and compassionate care. "Patients remember what doctors and nurses say, and that sometimes can be engraved in your mind forever." But the most important part, according to Kristin, is answering the questions from students. "Many students are really touched at an emotional level … and perhaps start to think they would consider a career in oncology or oncology-based research." Further research was critical for early detection and treatment options to be improved, Ms Evans said, particularly for the 55 per cent of gynaecological cancers considered rare or less common, which often had limited treatment options. "We want doctors to be curious about these diseases for the rest of their career," she said. "The most important thing is that GPs and nurses … have a voice in their head that is the woman's voice or the carer's voice that they take with them." Kristin said her own experience with ovarian cancer was proof that oncology research was having an impact. "I'm a 'super responder' on one of these new molecular-based treatments … so the prognosis that I had, which was very poor, I have now outlived this, and I know that that represents hope," she said. "Research is prolonging lives in some people and with more research it will prolong more lives." In addition to inspiring and educating the next generation of health professionals, she said the Survivors Teaching Students program had strengthened the community of people living with gynaecological cancer. "At the very personal level, I have made good friends, what I feel are lifelong friends. "The term lifelong is ironic in ovarian cancer because many of the women I have met … unfortunately have not had long lives. I have my contacts list and my phone is full of people who have passed away, but I never delete them." The program helped people affected by gynaecological cancer leave a "lasting legacy", Ms Evans added. "Many women and their families at the end of treatment are looking for a way to make a difference. Listen to the full story and subscribe to the Health Report podcast for more.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store